Recurrent Breast Cancer Presents as a Single Solid Ovarian Mass and Ascites

Abstract

In cases of pelvic tumors in patients who have a history of other primary cancers, metastasis should be suspected initially. Although the prognoses of these patients seem to be worse, intensive cytoreductive surgery would improve quality of life and offer a chance of better survival in highly selected patients.

Pelvic Recurrence of Breast Cancer Presenting as Ovarian Carcinoma: Case Report

“…The genital tract organs of patients with breast cancer should be carefully and routinely checked, not only for the possibility of endometrial lesions secondary to tamoxifen citrate treatment, but also for either primary or metastatic ovarian cancers. Prompt and intensive treatment may prolong survival and improve the quality of life [23]. We underline the usefulness of PET-CT in the evaluation of women suspected of distant recurrence of breast cancer.…”

“…Our patient is one of the few cases, reported in the literature, of pelvic recurrence from breast cancer. Chen in 2006 and Sheen-Chen in 2008 published, respectively, a case of primary breast cancer with metastasis to ovary and omentum and a case of metastatic ovarian cancer similar to the original breast carcinoma [23,24]. Diagnosis of pelvic metastatic tumor from breast origin is not simple.…”

Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report

“…While criteria used to identify metastatic carcinomas—and differentiate them from primary tumors—are mainly based on clinicopathologic findings, loss of heterozygosity (LOH) and mutational analysis may provide useful additional information, since prognosis and therapy of those two entities are different [7]. Furthermore, breast cancer metastasis to the ovaries with a prevalence from 10 to 30% is associated with BRCA1/2 mutation carriers, which have worse prognosis, and is usually diagnosed during autopsy, prophylactic or therapeutic oophorectomies, and as incidental findings during routine surgery [8]. To date, metastatic breast cancer is generally identified histologically by the positive expression of gross cystic disease fluid protein 15 (GCDFP15), mammaglobin, and GATA3 and by the lack of expression of PAX8, CA125, and WT1.…”